SpaceX won $739M in U.S. Space Force NSSL Phase 3 Lane 1 task orders to launch SDA and NRO missions from FY2026 to FY2028.
Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...
Cartesian Therapeutics, Inc. announced that it received FDA agreement on the design of its upcoming Phase 3 AURORA trial for Descartes-08, an mRNA cell therapy intended for treating myasthenia gravis ...
Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
10d
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback